NYSE$AORT

Artivion Inc · Q4 2019 earnings

Q4 2019 earnings · · Investor relations

Briefing

CryoLife's financial performance in Q4 2019 reflected revenue growth and progress on key initiatives.

CryoLife reported a 3% increase in total revenues for Q4 2019, reaching $69.7 million. The company's net loss was ($681,000), or ($0.02) per share, while non-GAAP net income was $3.8 million, or $0.10 per share.

  • Total revenues reached $69.7 million, a 3% year-over-year increase.
  • On-X® revenues increased by 18% compared to Q4 2018.
  • Net loss was ($681,000), or ($0.02) per fully diluted common share; non-GAAP net income was $3.8 million, or $0.10 per fully diluted common share.
  • Received approval to commence the PROACT Xa trial and secured European approval for two next-generation JOTEC products.

Headline financials

Total Revenue

$69.7M

Previous: $67.8M+2.8%
EPS (adj)

$0.10

Previous: $0.05+100.0%
Capital Expenditures

$2.85M

Previous: $1.51M+88.6%
Free Cash Flow

-$1.79M

Previous: $9.01M-119.9%
Net Income

-$681K

Previous: -$1.74M+60.9%
Operating Income

$3.63M

Previous: $2.78M+30.7%
Gross Profit

$46.6M

Previous: $45.2M+3.0%
Cash & Equivalents

$34.3M

Previous: $41.5M-17.3%
Total Assets

$606M

Previous: $571M+6.1%
Stock-Based Comp

$2.22M

Previous: $1.64M+35.2%

Revenue & EPS history

Artivion · Revenue · Quarterly

$69.7M

Q4 2019+2.8%vs Q4 2018
Beat estimate in 12 of 16 quarters(75%)
ActualEstimate

Revenue by segment

Artivion · $13.3M total across 1 segment · Q4 2019

  • On-X
    $13.3M

Forward guidance

CryoLife anticipates constant currency revenue growth of between 6.3% and 8.5% for the full year of 2020, with revenues expected to be in the range of $292 million to $298 million, assuming a Euro/USD exchange rate of 1.10. Non-GAAP earnings per share for 2020 are expected to be between $0.15 and $0.17.

Tailwinds

  • Constant currency revenue growth of between 6.3% and 8.5% for the full year of 2020.
  • Revenues are expected to be in the range of $292 million to $298 million, assuming a Euro/USD exchange rate of 1.10.
  • Non-GAAP earnings per share for 2020 are expected to be between $0.15 and $0.17.
  • Planned incremental investment in the Company’s pipeline.
  • Additional investment in our Asia Pacific and Latin American infrastructure.

Headwinds

  • 2020 revenue guidance assumes no contribution during 2020 from BioGlue® in China.
  • 2020 revenue guidance assumes no contribution during 2020 from PerClot® in the U.S.
  • 2020 revenue guidance assumes no contribution during 2020 from TMR handpieces.
  • Non-GAAP earnings per share reflect approximately $0.12 per share in planned incremental investment in the Company’s pipeline.
  • An estimated $0.06 per share additional investment in our Asia Pacific and Latin American infrastructure.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2019

Historical avgQ4 2019

+1.0%

Avg return

Earnings day

+1.1%

Avg return

5 days after

+3.3%

Avg return

30 days after

52%

33 / 64 earnings

Positive

+23.5%

Q1 2021

Best reaction

-15.7%

Q4 2016

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.8%-36.8%-43.2%
Q3 2025-5.9%+0.3%-6.1%
Q1 2025+14.9%+21.6%+22.5%
Q4 2024-8.2%-8.8%-12.0%
Q3 2024-2.5%-5.8%+0.7%
Q2 2024-1.2%-0.3%-0.2%
Q1 2024+13.6%+12.4%+12.0%
Q4 2023+7.1%+6.5%+12.5%
Q3 2023+10.5%+7.1%+40.6%
Q2 2023-3.3%-1.7%+1.9%
Q1 2023+12.7%+9.1%+13.4%
Q4 2022+4.3%-1.5%-11.7%
Q3 2022-1.9%-3.2%+18.7%
Q2 2022-1.8%-1.2%-3.9%
Q1 2022-11.4%-21.6%-12.4%
Q4 2021-0.1%-1.7%+22.4%
Q3 2021+4.3%+2.6%-16.1%
Q2 2021+1.3%+1.2%-2.6%
Q1 2021+23.5%+21.1%+22.0%
Q4 2020+0.8%+1.1%+1.3%
Q3 2020-4.9%+10.5%+17.1%
Q2 2020+1.6%+4.7%+7.3%
Q1 2020-4.0%-2.0%-1.6%
Q4 2019-8.1%-9.3%-27.2%
Q3 2019-7.7%-3.4%+1.7%
Q2 2019-4.6%-6.3%-11.4%
Q1 2019+2.1%+4.0%-5.5%
Q4 2018-15.2%-4.6%+0.1%
Q3 2018-4.7%-1.1%-3.3%
Q2 2018+9.4%+10.1%+15.9%
Q1 2018+6.2%+12.3%+22.9%
Q4 2017+12.8%+9.9%+0.8%
Q3 2017-2.7%-4.8%+1.8%
Q2 2017+3.1%-1.3%-1.6%
Q1 2017+13.2%+12.6%+12.3%
Q4 2016-15.7%-9.7%-11.5%
Q3 2016-1.5%+0.0%+18.2%
Q2 2016+14.6%+21.4%+28.2%
Q1 2016-1.8%
Q4 2015+12.6%
Q3 2015+11.1%
Q2 2015-0.4%
Q1 2015+4.0%
Q4 2014-4.2%
Q3 2014-6.1%
Q2 2014+6.4%
Q1 2014-6.0%
Q4 2013-9.1%
Q3 2013+10.6%
Q2 2013-5.4%
Q1 2013-5.4%
Q4 2012+2.0%
Q3 2012+0.5%
Q2 2012-4.3%
Q1 2011+0.2%
Q1 2012+5.1%
Q4 2009-11.5%
Q4 2011-11.5%
Q3 2010+4.6%
Q3 2011+4.6%
Q2 2011+5.4%
Q2 2010+5.4%
Q4 2010+5.4%
Q1 2010+3.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro